Plus Therapeutics Presents Promising Data from Clinical Trials; “Significant Clinical Interest” in Field
Clinical-stage pharmaceutical company, Plus Therapeutics (Nasdaq:PSTV), has presented data from two clinical trials evaluating its targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL) at the 35th Annual Congress of the European Association of Nuclear Medicine.
The Company’s ReSPECT-GBM presentation was selected for inclusion in the opening Plenary Highlights Lecture, signaling significant clinical interest in the field.
- 186RNL is being evaluated for the treatment of leptomeningeal metastases and recurrent glioblastoma;
- Treatment was well tolerated without dose limiting toxicities and all patients showed a decrease in spinal fluid tumor cell counts;
- Plus Therapeutics’ leptomeningeal metastases trial is supported by a $17.6 million grant by the Cancer Prevention & Research Institute of Texas;
- The Company plans to initiate a National Institutes of Health (NIH)-funded Phase 2 study in recurrent glioma by the end of 2022.
Plus Therapeutics develops, manufactures, and commercializes complex and innovative treatments for cancer and other life-threatening diseases.